The global apoptosis receptor BAX market is anticipated to grow at a significant CAGR of 6.2% during the forecast period 2022-2028. The rising biomedical research activities is a major factor attributing to the growth of the market. For instance, according to the research paper published on BMJ Publishing Group Ltd & British Society of Gastroenterology in February 2022, the Bax/Bcl-2 system did not seem to be involved in induction of apoptosis of epithelial cells in the inflamed colonic mucosa of UC. Similarly, the scientists of Albert Einstein College of Medicine in March 2022 had found that the combination of BTSA1.2 and Navitoclax is effective against the treatment of various types of cancer as BTSA1.2 boosting active BAX to toxic levels in cancer cells, and Navitoclax acting as BAX's bodyguard by preventing BCL-XL from neutralizing BAX. Such researches are further expected to generate growth opportunities for the market in the future.
Browse the full report description “Global Apoptosis Regulator BAX Market Size, Share, and Trends Analysis Report by Type (GM-6, HU-010, LTX-401, and Others) and by Application (Liver Cancer, Stroke, Melanoma, Parkinson’s Disease, and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/apoptosis-regulator-bax-market
The market players are also contributing significantly in the growth of the global apoptosis receptor BAX market by adopting various business strategies, such as mergers and acquisitions, regional expansion, partnerships and collaborations, and new product releases to remain competitive in the market. For instance, in August 2020, Verrica Pharmaceuticals entered into an exclusive global licensing agreement with Lytix Biopharma to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. LTX-315 (Ruxotemitide) is a potential candidate in the soft tissue sarcoma pipeline owing to its ability to fully personalize immunotherapy by its mode of action to use the patient’s own tumor as its own vaccine, expose the immune system to one patient’s own cancer antigens, and generate patient-specific antitumor immunity. LTX-315 is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape - including, Genervon Biopharmaceuticals LLC, Lytix Biopharma AS, Huons Co. Ltd., among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Apoptosis Receptor BAX Market Report Segment
By Type
By Application
Global Apoptosis Receptor BAX Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/apoptosis-regulator-bax-market